During Q4 2018 the big money sentiment decreased to 1.03. That’s change of 0.22, from 2018Q3’s 1.25. 18 investors sold all, 130 reduced holdings as Charles River Laboratories International, Inc. ratio turned negative. 94 rose holdings while 58 funds bought holdings. Funds hold 46.68 million shares thus 3.25% more from 2018Q3’s 45.21 million shares.
Hood River Capital Mgmt Limited Co accumulated 311,932 shs. Congress Asset Mgmt Ma holds 1.31% or 768,534 shs. Macquarie Gru holds 0% or 100 shs in its capital. Snyder Cap Mngmt L P reported 71,104 shs stake. Van Berkom Assoc reported 584,051 shs or 2.33% of all its holdings. Louisiana State Employees Retirement System has invested 0.08% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Wells Fargo & Company Mn holds 0.06% or 1.47M shs in its capital. Texas Permanent School Fund holds 0.06% or 31,473 shs. The Maryland-based Price T Rowe Associates Md has invested 0.01% in Charles River Laboratories International, Inc. (NYSE:CRL). Citigroup Inc holds 0% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL) for 24,678 shs. Principal Fincl Group owns 0.03% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 211,897 shs. Mutual Of America Lc holds 0.08% or 42,373 shs in its capital. Systematic Fin Mngmt Lp holds 0.03% or 9,684 shs in its capital. Jane Street Limited Company stated it has 0% of its capital in Charles River Laboratories International, Inc. (NYSE:CRL). Employees Retirement Association Of Colorado owns 10,063 shs.

Charles River Laboratories International, Inc. registered $6.45 million net activity with 0 buys and 4 insider sales since November 7, 2018. FOSTER JAMES C sold $2.88 million worth of Charles River Laboratories International, Inc. (NYSE:CRL) on Tuesday, January 8. Shares for $3.18 million were sold by JOHST DAVID P on Wednesday, November 7.

Charles River Laboratories International, Inc. (NYSE:CRL)’s quarterly earnings will be revealed on May, 9., according to Zacks. Analysts forecast $1.40 EPS, which is $0.02 up or 1.45 % from 2018’s $1.38 EPS. This could hit $68.24 million profit for CRL assuming the current $1.40 EPS will become reality. Analysts at Wall Street see Charles River Laboratories International, Inc.’s -6.04 % negative EPS growth compared to $1.49 EPS for last quarter. CRL touched $144.39 during the last trading session after $0.18 change.Charles River Laboratories International, Inc. has volume of 337,124 shares. Since April 14, 2018 CRL has risen 34.55% and is uptrending. The stock outperformed the S&P 500 by 30.18%.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

Total analysts of 8 have positions in Charles River (NYSE:CRL) as follows: 6 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 75%. Since November 8, 2018 according to StockzIntelligence Inc Charles River has 10 analyst reports. The stock rating was maintained by Jefferies with “Buy” on Wednesday, February 13. On Monday, March 11 the stock has “Overweight” rating by KeyBanc Capital Markets. On Tuesday, March 12 the company was maintained by Jefferies. The company rating was maintained by RBC Capital Markets on Thursday, November 8. On Monday, March 18 the stock has “Hold” rating by Barclays Capital. In Thursday, November 8 report Raymond James maintained it with “Outperform” rating and $150 target. On Thursday, March 14 the company was maintained by Argus Research. On Thursday, November 8 Robert W. Baird maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating. Robert W. Baird has “Outperform” rating and $148 target. On Monday, December 3 Morgan Stanley maintained the shares of CRL in report with “Equal-Weight” rating.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide.The firm is worth $7.04 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).The P/E ratio is 31.25. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

For more Charles River Laboratories International, Inc. (NYSE:CRL) news published recently go to: Globenewswire.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Report: Developing Opportunities within Bristol-Myers Squibb, AutoNation, FirstEnergy, Charles River Laboratories International, Yum! Brands, and AGNC Investment — Future Expectations, Projections Moving into 2019 – GlobeNewswire” published on March 25, 2019, “Charles River Laboratories International, Inc. 2018 Q4 – Results – Earnings Call Slides – Seeking Alpha” on February 13, 2019, “Charles River Laboratories Q4 2018 Earnings Preview – Seeking Alpha” with a publish date: February 12, 2019, “Charles River Labs Has A Great, Long-Term Story To Tell – Seeking Alpha” and the last “Charles River Labs teams up with Atomwise in drug design – Seeking Alpha” with publication date: January 11, 2019.